pH对克拉霉素体外抗鸟分枝杆菌复合群效力的影响。
Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.
作者信息
Truffot-Pernot C, Ji B, Grosset J
机构信息
Faculté de Médecine Pitié-Salpetrière, Paris, France.
出版信息
Antimicrob Agents Chemother. 1991 Aug;35(8):1677-8. doi: 10.1128/AAC.35.8.1677.
Abstract
Employing 7H11 agar medium at pH 6.6, the MICs of clarithromycin for 50% (MIC50) and 90% (MIC90) of 19 strains of Mycobacterium avium complex were 8 and 16 micrograms/ml, respectively. However, the MICs were 2 to 3 log2 dilutions lower in the 7H11 medium adjusted to pH 7.4, and the MICs on 10% OADC (oleic acid-albumin-dextrose-catalase)-enriched Mueller-Hinton agar at pH 7.3 were also 2 log2 dilutions lower than those measured on 7H11 agar at pH 6.6. Therefore, clarithromycin is more active at a physiologic than at an acidic pH.
摘要
在pH值为6.6的7H11琼脂培养基中，19株鸟分枝杆菌复合群菌株中50%（MIC50）和90%（MIC90）的克拉霉素最低抑菌浓度分别为8微克/毫升和16微克/毫升。然而，在pH值调至7.4的7H11培养基中，最低抑菌浓度低2至3个log2稀释度，并且在pH值为7.3的添加10%OADC（油酸-白蛋白-葡萄糖-过氧化氢酶）的Mueller-Hinton琼脂上的最低抑菌浓度也比在pH值为6.6的7H11琼脂上测得的低2个log2稀释度。因此，克拉霉素在生理pH值下比在酸性pH值下活性更高。
相似文献
1
Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex.pH对克拉霉素体外抗鸟分枝杆菌复合群效力的影响。
Antimicrob Agents Chemother. 1991 Aug;35(8):1677-8. doi: 10.1128/AAC.35.8.1677.
2
Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium.克拉霉素对鸟分枝杆菌的最低抑菌浓度和杀菌浓度
Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):856-8. doi: 10.1164/ajrccm/145.4_Pt_1.856.
3
Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial.克拉霉素对获得性免疫缺陷综合征患者鸟分枝杆菌感染的活性。一项对照临床试验。
Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564-9. doi: 10.1164/ajrccm/144.3_Pt_1.564.
4
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.将司帕沙星、阿奇霉素、替马沙星和利福喷丁与克拉霉素针对鸟分枝杆菌复合群在人巨噬细胞内增殖的活性进行比较。
Antimicrob Agents Chemother. 1991 Jul;35(7):1356-9. doi: 10.1128/AAC.35.7.1356.
5
In vitro activity of clarithromycin alone or in combination with other antimicrobial agents against Mycobacterium avium-intracellulare. Complex strains isolated from AIDS patients.克拉霉素单独或与其他抗菌药物联合对鸟分枝杆菌-胞内分枝杆菌复合体菌株的体外活性。从艾滋病患者中分离出的菌株。
J Chemother. 1991 Dec;3(6):357-62. doi: 10.1080/1120009x.1991.11739120.
6
In vitro and in vivo activities of clarithromycin against Mycobacterium avium.克拉霉素对鸟分枝杆菌的体外及体内活性
Antimicrob Agents Chemother. 1989 Sep;33(9):1531-4. doi: 10.1128/AAC.33.9.1531.
7
Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages.克拉霉素、磺胺异恶唑和利福布汀对人巨噬细胞内鸟分枝杆菌复合群增殖的作用。
Antimicrob Agents Chemother. 1990 Aug;34(8):1508-11. doi: 10.1128/AAC.34.8.1508.
8
In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex.克拉霉素联合乙胺丁醇和利福平对鸟分枝杆菌复合群的体外试验
Infection. 1991 Sep-Oct;19(5):343-5. doi: 10.1007/BF01645362.
9
Clarithromycin against Mycobacterium avium complex infections.克拉霉素治疗鸟分枝杆菌复合群感染
Tuber Lung Dis. 1996 Feb;77(1):19-26. doi: 10.1016/s0962-8479(96)90070-2.
10
Bacteriostatic and bactericidal activities of gentamicin alone and in combination with clarithromycin against Mycobacterium avium.庆大霉素单独及与克拉霉素联合对鸟分枝杆菌的抑菌和杀菌活性
Antimicrob Agents Chemother. 1992 Aug;36(8):1695-8. doi: 10.1128/AAC.36.8.1695.
引用本文的文献
1
Rational Choice of Antibiotics and Media for Complex Drug Susceptibility Testing.复杂药敏试验中抗生素与培养基的合理选择
Front Microbiol. 2020 Feb 19;11:81. doi: 10.3389/fmicb.2020.00081. eCollection 2020.
2
NTM drug discovery: status, gaps and the way forward.NTM 药物发现：现状、差距和未来发展方向。
Drug Discov Today. 2018 Aug;23(8):1502-1519. doi: 10.1016/j.drudis.2018.04.001. Epub 2018 Apr 7.
3
Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.鸟分枝杆菌复合群感染小鼠模型的特征分析及药物组合评估
Antimicrob Agents Chemother. 2015 Apr;59(4):2129-35. doi: 10.1128/AAC.04841-14. Epub 2015 Jan 26.
4
Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy.改进治疗嗜沫分枝杆菌的现有工具：药物组合评估及感染和化疗小鼠模型的特征分析。
J Antimicrob Chemother. 2013 Mar;68(3):659-65. doi: 10.1093/jac/dks421. Epub 2012 Nov 5.
5
Prevention of the selection of clarithromycin-resistant Mycobacterium avium-intracellulare complex.预防克拉霉素耐药鸟分枝杆菌复合群的产生。
Drugs. 1997;54 Suppl 2:23-7; discussion 28-9. doi: 10.2165/00003495-199700542-00006.
6
The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.吞噬体环境可保护强毒鸟分枝杆菌免受克拉霉素的杀伤和破坏。
Infect Immun. 1997 Jul;65(7):2792-802. doi: 10.1128/iai.65.7.2792-2802.1997.
7
A randomized comparison of two clarithromycin doses for treatment of Mycobacterium avium complex infections.两种克拉霉素剂量治疗鸟分枝杆菌复合群感染的随机对照比较。
Infection. 1997 Jan-Feb;25(1):16-21. doi: 10.1007/BF02113501.
8
Susceptibility testing of Mycobacterium avium complex isolates.鸟分枝杆菌复合体分离株的药敏试验
Antimicrob Agents Chemother. 1996 Aug;40(8):1759-67. doi: 10.1128/AAC.40.8.1759.
9
Clarithromycin is inactive against Mycobacterium tuberculosis.克拉霉素对结核分枝杆菌无活性。
Antimicrob Agents Chemother. 1995 Dec;39(12):2827-8. doi: 10.1128/AAC.39.12.2827.
10
Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex.克拉霉素单独及联合乙胺丁醇对鸟分枝杆菌复合群的抗生素后效应
Antimicrob Agents Chemother. 1995 Dec;39(12):2803-6. doi: 10.1128/AAC.39.12.2803.
本文引用的文献
1
Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin.二氧化碳和pH值对脆弱拟杆菌群对红霉素敏感性的影响。
Antimicrob Agents Chemother. 1981 Feb;19(2):335-6. doi: 10.1128/AAC.19.2.335.
2
Effect of pH on the activity of erythromycin against 500 isolates of gram-negative bacilli.pH对红霉素针对500株革兰氏阴性杆菌活性的影响。
Appl Microbiol. 1970 Nov;20(5):754-6. doi: 10.1128/am.20.5.754-756.1970.
3
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.一种新型大环内酯类药物A-56268与罗红霉素、红霉素及克林霉素的体外活性比较
Antimicrob Agents Chemother. 1987 Feb;31(2):343-5. doi: 10.1128/AAC.31.2.343.
4
In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.新型大环内酯类药物A-56268（TE-031）的体外和体内评估
Antimicrob Agents Chemother. 1986 Dec;30(6):865-73. doi: 10.1128/AAC.30.6.865.
5
In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin.阿奇霉素（CP 62,993）、克拉霉素（A - 56268；TE - 031）、红霉素、罗红霉素及克林霉素的体外活性
Antimicrob Agents Chemother. 1988 May;32(5):752-4. doi: 10.1128/AAC.32.5.752.
6
In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.几种新型大环内酯类抗生素对鸟分枝杆菌复合体的体外活性
Antimicrob Agents Chemother. 1989 Sep;33(9):1614-6. doi: 10.1128/AAC.33.9.1614.
7
Comparative in-vitro activity of twenty antimicrobial agents against clinical isolates of Mycobacterium avium complex.二十种抗菌剂对鸟分枝杆菌复合群临床分离株的体外活性比较
J Antimicrob Chemother. 1989 Nov;24(5):667-73. doi: 10.1093/jac/24.5.667.
8
In vitro and in vivo activities of clarithromycin against Mycobacterium avium.克拉霉素对鸟分枝杆菌的体外及体内活性
Antimicrob Agents Chemother. 1989 Sep;33(9):1531-4. doi: 10.1128/AAC.33.9.1531.
Zotero 插件